Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2013. The report details a specific share repurchase transaction executed on June 5, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 860,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,698.0 pence per share; lowest price paid was 1,670.0 pence per share.
- Treasury Holdings (Settled): 504,734,512 shares (9.30% of total issued share capital).
- Treasury Holdings (Including Unsettled): 507,234,512 shares (10.30% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,924,459,253 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 860,000 shares for treasury. This action increased the percentage of total voting rights held in treasury from the prior level to 10.30% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,924,459,253) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current treasury share count and its impact on total voting rights (10.30% including unsettled shares).
- Note that this announcement does not constitute an offer to purchase or subscribe for securities.